Full-Time

Senior Engineer

Site Mechanical Engineer

Posted on 8/23/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$119.2k - $147.9k/yr

Holly Springs, NC, USA

In Person

Category
Mechanical Engineering (1)
Requirements
  • High school diploma / GED and 10 years of Maintenance or Engineering experience OR
  • Associate’s degree and 8 years of Maintenance or Engineering experience OR
  • Bachelor’s degree and 4 years of Maintenance or Engineering experience OR
  • Master’s degree and 2 years of Maintenance or Engineering experience OR
  • Doctorate degree
Responsibilities
  • Provide system ownership during capital project execution phases, focusing on building mechanical, HVAC/R systems, Life Safe Gas Detection systems, and subsystems.
  • Collaborate with capital project team to ensure systems are designed, installed and operated safely, in compliance with pertinent environmental health/safety practices, regulations, as well as Amgen procedures and standards.
  • Support equipment factory test and site acceptance test (FAT/SAT) activities.
  • Support installation, commissioning, and qualification of Mechanical and HVAC systems and work with Qualified Building Automation System (QBAS) system provider (OEM), Amgen Engineering Technical Authority (ETA), Amgen site engineers, and other third parties to ensure Amgen user requirements are met.
  • Work with and lead third-party contractors to support startup, installation check-out, and air system balancing.
  • Support construction related activities, such as field verification of equipment layout, maintenance access, accurate use of materials and components (e.g. Fire Protection system), ensuring system interlocking and sequence of operations are engineered and configured accurately within the QBAS.
  • Help develops standard operating procedures and maintenance practices for mechanical and HVAC systems.
  • Implement master maintenance plans (MMP) and spare parts' inventory required to ensure long term systems reliability for mechanical and HVAC systems.
  • Provide ongoing system ownership for site mechanical and HVAC systems operation and maintenance.
  • Responsible for continuous improvement projects to drive operational efficiencies, reliability, and enhance safety.
  • Own and maintain related drawings, schedules, zoning diagrams, and operating procedures for mechanical and HVAC systems.
  • Work with electrical system owner to ensure electrical systems are working appropriately for mechanical and HVAC systems.
  • Responsible to support electrical outages and HVAC system restarts to avoid impact to plant operations.
  • Ensure plant readiness and Quality and Regulatory compliance for internal and external audits related to the Mechanical/HVAC systems.
  • Collaborate with Amgen network sites to align and share good engineering practices for Mechanical/HVAC systems.
  • Support trouble shooting and calibration activities for mechanical measurement and instrumentation (including validated humidity, temperature, and room differential pressure monitoring systems, as well as life safety gas detection systems).
  • Ensure room pressurization strategy, control, testing, and documentation requirements for GMP classified manufacturing space are consistently maintained.
  • Own and maintain HEPA/ULPA filter certification program, as well as certification of unidirectional booths, bio-safety cabinets, and fume hoods.
  • As the system owner, provide recommendations on facility changes affecting mechanical and HVAC systems and support project implementation.
  • Responsible for SLCM by working with Global Lifecycle Asset Management team to ensure system lifecycle are current and maintained.
  • Work with original equipment manufacturers and integrated service providers for breakdown and planned maintenance.
  • Provide rotational on-call support and ensure 24x7 day-to-day reliability of Mechanical/HVAC systems for plant operations.
Desired Qualifications
  • Bachelor’s Degree in Engineering or related field.
  • 6+ years’ experience in engineering or maintenance or related function within the biotechnology and/or pharmaceutical and/or Medical Device industry.
  • 5+ years’ experience and track record of ensuring compliance in a highly regulated environment.
  • Experience working in a regulated environment (e.g. cGMP, OSHA, EPA, etc.) and experience interacting with regulatory agencies and inspectors.
  • Familiarity with GMP quality systems/processes such as change control, non-conformances, corrective and preventative actions, and qualifications/validation.
  • Solid understanding of the following routine engineering tasks and systems: Maintenance and asset management systems (e.g. IBM Maximo), building automation system operation, navigation, and reporting, vibration monitoring and analysis, equipment sizing, selection, installation, and maintenance, ductwork and piping sizing, design, installation, and maintenance, air handling system psychrometrics, Freezer and cold storage refrigeration systems, and equipment operation & maintenance (HVAC control systems, air handlers, fans, coils, humidifiers, filters and filtration, terminal devices, refrigeration equipment, compressors, chillers, pumps, cooling towers, boilers, HEPA filters, including testing & certification, fume hoods and biosafety cabinets, including testing & certification) and system and equipment trouble shooting.
  • Technical experience with critical and non-critical utilities systems (such as HVAC serving Grade 7/8/9 manufacturing space, Clean Steam, Process Compressed Air, etc).
  • Ability to work independently, handle multiple tasks in project settings, and proficiency in communication, facilitation, and collaboration.
  • CEM (Certified Energy Managers) by Association of Energy Engineers is desirable.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE